The Haystack Project
  • Home
  • About Us Participants Partners Board and Advisors
  • Priorities
  • PROTECT Rare
  • Rare Disease Approvals HEART Act
  • Speaker Series Payer Engagement Health Equity Rare Cancer
  • Inflation Reduction Act Medicare Section 340b Medicaid FDA ICER
  • Patient Stories
  • Join
  • Take Action
The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Blue-Banner.png
The Haystack Project

Medicaid

The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Featured
Haystack Data Elements ipay2027
Sep 3, 2024
Haystack Data Elements ipay2027
Sep 3, 2024
Sep 3, 2024
Haystack mdpnp Guidance ipay2027 Comment
Jul 8, 2024
Haystack mdpnp Guidance ipay2027 Comment
Jul 8, 2024
Jul 8, 2024
RFI on Improving and Protecting Access to Gene Therapies
Jan 25, 2024
RFI on Improving and Protecting Access to Gene Therapies
Jan 25, 2024
Jan 25, 2024
Haystack Comments on CMS Proposed Evidence Standards NCD
Aug 21, 2023
Haystack Comments on CMS Proposed Evidence Standards NCD
Aug 21, 2023
Aug 21, 2023
Haystack's Comments on Craft of bill on State Integrated Care Programs for Dual Eligible Individuals
Jul 3, 2023
Haystack's Comments on Craft of bill on State Integrated Care Programs for Dual Eligible Individuals
Jul 3, 2023
Jul 3, 2023
Haystack Comments on CMI's Proposed Rule on Ensuring Medicaid Access
Jul 3, 2023
Haystack Comments on CMI's Proposed Rule on Ensuring Medicaid Access
Jul 3, 2023
Jul 3, 2023
Haystack's comments on CMS’ proposed rule on the Medicaid and Children’s Health Insurance Program (CHIP)
Jul 3, 2023
Haystack's comments on CMS’ proposed rule on the Medicaid and Children’s Health Insurance Program (CHIP)
Jul 3, 2023
Jul 3, 2023
Haystack IRA data elements ICR 5.22.23
May 22, 2023
Haystack IRA data elements ICR 5.22.23
May 22, 2023
May 22, 2023
Haystack Responds to HHS RFI on Improving Primary Care
Aug 1, 2022
Haystack Responds to HHS RFI on Improving Primary Care
Aug 1, 2022
Aug 1, 2022
Tuberous Sclerosis Alliance opposes MACPAC recommendations regarding differential Medicaid rebates for FDA accelerated approval drugs
Aug 10, 2021
Tuberous Sclerosis Alliance opposes MACPAC recommendations regarding differential Medicaid rebates for FDA accelerated approval drugs
Aug 10, 2021
Aug 10, 2021

 
 
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/

The Haystack Project

Act Now

Engage in our efforts to support Ultra Rare advocacy.

Act Now
 

Join Haystack Project

Get news and updates and engage in Ultra Rare advocacy. Sign up to join our community today.

Join Us
 

Keep up-to-date with current events at Haystack!

View past newsletters

About Us

The Issues

Resources

News & Updates

© 2020 Haystack Project. All Rights Reserved. 

 

Contact Us

Please consider making a tax-deductible donation to support the Haystack Project today.

The Haystack Project is a 501(c)3 nonprofit that brings together patients organizations representing patients suffering from or caring for patients with extremely rare diseases. Our mission is to educate policymakers and other stakeholders about the need for policies that recognize the unique circumstances of extremely rare conditions and treatments and expand incentives critical to ensuring they can reach patients.